Samsung Bioepis starts Phase 1 trial for SBE303 ADC

Apr 15, 2026, 10:40 am

		0
Samsung Bioepis headquarters in Incheon, Korea/ Source: Samsung Bioepis

Samsung Bioepis announced Tuesday the initiation of a Phase 1 clinical trial for SBE303, its first novel antibody-drug conjugate (ADC) candidate targeting Nectin-4.

SBE303 is designed to bind to Nectin-4, an adhesion protein specifically expressed in tumor cells, including urothelial, lung, and breast cancers. The company said the candidate represents a significant step in expanding its oncology pipeline.

The Phase 1 study is an open-label, multi-center, first-in-human trial aimed at evaluating the safety, tolerability, and efficacy of SBE303 in patients with advanced refractory solid tumors. Details of the trial are available on ClinicalTrials.gov under the identifier NCT07524348.

Founded in 2012, Samsung Bioepis is a biopharmaceutical company focused on improving access to healthcare. As a wholly owned subsidiary of Samsung Epis Holdings, the company continues to develop a broad pipeline of biologic candidates across multiple therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology.

#Samsung Bioepis #SBE303 #ADC #Nectin-4 #clinical trial